News | Interventional Radiology | March 19, 2021

Minimally Invasive Treatment Provides Fast Pain Relief for Cancer Patients

Patients with debilitating bone tumors experienced improved quality of life in as little as three days

Radiofrequency ablation for the palliative treatment of osseous metastases reduces pain and improves quality of life

Radiofrequency ablation for the palliative treatment of osseous metastases reduces pain and improves quality of life.

March 19, 2021 — A minimally invasive treatment for patients whose cancer has spread to their bones provides quick and sustained pain relief and improves quality of life, according to a new study to be presented at the Society of Interventional Radiology Annual Scientific Meeting. The palliative treatment known as radiofrequency ablation (RFA) is effective in providing relief in as little as three days, and the benefits last more than 12 months — a significant improvement over radiation treatment.

“Commonly used radiation treatments can take weeks to provide pain relief,” said Jason R. Levy, M.D., a vascular and interventional radiologist at Northside Hospital in Atlanta and lead researcher of the study. “A few weeks can represent a large portion of the remaining life in these patients, and RFA may be able to give them the best quality of life possible in the time they have left.”

RFA is a minimally invasive treatment that uses radiofrequency waves to create heat that kills tumor cells and destroys nerve fibers to reduce or stop transmission of pain signals to the brain. In this study, RFA was used to treat painful metastatic bone lesions and was followed up with cement injection to help stabilize the bone. The cement helped prevent fractures that are known to result following other treatments, such as radiation.

Researchers enrolled 218 cancer patients at 15 sites around the world between October 2017 and February 2020. Patients completed questionnaires to measure their quality of life and pain levels prior to the procedure, three days after and then intermittently through the one-year mark. Researchers used both the five-level EurolQol scale and the European Organization for Research and Treatment of Cancer Quality of Life (EORTC) measurement.

Significant improvements were seen in 59 subjects who completed the EurolQol at 12 months and similar improvements were seen for 14 patients who completed the 12-month EORTC Qol. Because of the palliative nature of the treatment, many patients were unable to be surveyed through the entire 12- month milestone.

“What set our results apart from prior research is the sheer speed and durability of this treatment,” said Levy. “As a result, we believe this treatment should be available to more patients with metastatic cancer earlier in their treatment path.”

The research focused on lytic bone metastases, a common type of bone tumor found in many cancer patients, making the treatment an option for a wide range of cancer patients. Predominant initial cancers in this study were breast, lung and kidney.

A limitation of the study was that many patients were lost to follow-up due to deaths related to the underlying cancer. The research was funded by Medtronic.

For more information: sirmeeting.org

Related Content

#SiemensHealthineers #Varian #Siemens The transformative combination accelerates the company’s impact on #global #healthcare and establishes a strong partner for #customers and #patients along the entire #cancer care continuum and for many of the most threatening #diseases
News | Radiology Business | April 15, 2021
April 15, 2021 — Siemens Healthineers AG an
The U.S. Food and Drug Administration (#FDA) authorized marketing of #Medtronic's #GIGenius, the first device that uses #artificialintelligence (#AI) based on #machinelearning to assist #clinicians in detecting #lesions (such as #polyps or suspected tumors) in the #colon in real time during a c#olonoscopy.

The GI Genius intelligent endoscopy module works in real-time, automatically identifying and marking (with a green box) abnormalities consistent with colorectal polyps, including small flat polyps.

News | Artificial Intelligence | April 12, 2021
Varian announced it is collaborating with Google Cloud to build an advanced artificial intelligence (AI) based diagnostic platform to aid in the fight against cancer. Varian and Google Cloud AI embarked on a deployment journey, using Neural Architecture Search (NAS) technology via Google Cloud AI Platform, to create AI models for organ segmentation — a crucial and labor-intensive step in radiation oncology that can be a bottleneck in the cancer treatment clinical workflow.
News | Artificial Intelligence | April 08, 2021
April 8, 2021 — Varian announced it is collaborating with Google...
Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, announced today that it has signed a definitive agreement to be acquired by Hologic, Inc., a global leader in women's health, for an enterprise value of approximately $795 million.  This includes a cash payment of approximately $714 million for Mobidiag’s equity, and net debt of approximately $81 million.
News | Women's Health | April 08, 2021
April 8, 2021 — Mobidiag Oy, a privately held, commercial-stage F
Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

Brain tumors edged out by artificial intelligence: VBrain applies auto-contouring to the three most common types of brain tumors: brain metastasis, meningioma and acoustic neuroma.

News | Artificial Intelligence | April 07, 2021
April 7, 2021 — Vysioneer, a leader in a...
The National Comprehensive Cancer Network® (NCCN®) and the American Cancer Society (ACS) are teaming up with leading health organizations across the country to endorse the safe resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.
News | Radiation Therapy | March 31, 2021
March 31, 2021 — Doctors who oversee cancer clinics say that new patients are arriving for treatment with more advanc
Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Ultimately, because LYFS-CT may exclude minority patients who could benefit from LCS and underestimate the benefits of LCS, the authors of this AJR article suggested "augmenting LCS eligibility for minority patients using combinations of models"--specifically, the PLCOm2012 model in conjunction with LYFS-CT and USPSTF-2020. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Lung Imaging | March 29, 2021
March 29, 2021 — According to ARRS' 
Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

News | Radiopharmaceuticals and Tracers | March 26, 2021
March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of